Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The aim of this study was to assess the anxiolytic and sedative effect of OZALIN® / OZASED® (ADV6209) 0,25mg/Kg in children undergoing magnetic resonance imaging (MRI) under inhalational anesthesia. Our hypothesis is that compared to children who do not receive any premedication, palatability of OZALIN® / OZASED® by allowing an easier acceptance of the drug, improves the quality of anesthesia induction and postoperative behavioral outcome improving sedation and reducing the need for inhalation anesthetic which has been recognized as the main cause of post-procedural behavioral changes, including emergence agitation.
Magnetic resonance imaging is considered the primary investigative tool for evaluating a wide range of paediatric medical conditions. Sedatives are often needed in this population to ensure immobilization during the acquisition of the images.
Midazolam has always been the most used anxiolytic-sedative drug in the pediatric population. Over time, the intravenous formulation of midazolam has been used also for oral, nasal or rectal administration but those alternative routes of administration represent an off-label use. Recently, in Europe was licensed ADV6209, a midazolam solution for oral use containing gamma-cyclodextrin (OZALIN® / OZASED®).
The aim of this study was to assess its anxiolytic and sedative effect at a dosage of 0,25mg/Kg in children undergoing magnetic resonance imaging (MRI) under inhalational anesthesia. Our hypothesis is that compared to children who do not receive any premedication, palatability of OZALIN® / OZASED® by allowing an easier acceptance of the drug, improves the quality of anesthesia induction and postoperative behavioral outcome improving sedation and reducing the need for inhalation anesthetic which has been recognized as the main cause of post-procedural behavioral changes, including emergence agitation.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Ozased group | 50 patients premedicated with OZALIN® / OZASED® | ||
| Control group | 50 patients who did not receive any premedication |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| evaluation of patients' reactive behavior to facemask positioning for inhalational anesthesia induction. | evaluation of patients' reactive behavior to facemask positioning for inhalational anesthesia induction evaluated on a four-point scale (Mask Acceptance Scale, MAS) indicating that child is cooperative and accept the mask readily (MAS=1), he is slight fearful and accepts the mask with mild resistance (MAS=2), with moderate struggle (MAS=3) or he resists strongly and must be restrained (MAS=4) | 30 minutes within premedication administration |
| Measure | Description | Time Frame |
|---|---|---|
| the percentage of sevoflurane at which the child's eyes closed upon induction of general anesthesia | the percentage of sevoflurane at which the child's eyes closed upon induction of general anesthesia; | procedure (at induction of general anesthesia) |
| time to eye closure at induction of anesthesia; |
Not provided
Inclusion Criteria:
- We included in the study 100 children (either gender), aged 1-10 years, American Society of Anaesthesiologists (ASA) physical status 1 and 3 who, between March and December 2022, received inhalation anesthesia for brain and spinal cord MRI for diagnostic investigations or postoperative and oncological follow-up
Exclusion Criteria:
Not provided
Not provided
the IRCCS Agostino Gemelli Foundation of Catholic University of Rome
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Rossella Garra | Fondazione Policlinico A. gemelli IRCCS | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Fondazione Policlinico Agostino Gemelli IRCCS | Rome | 00135 | Italy |
Non completely planned yet
Non completely planned yet
Not completely planned yet
Not provided
Not provided
Not provided
Not provided
Not provided
time to eye closure at induction of anesthesia |
| procedure (at induction of general anesthesia) |
| patient degree of acceptance of the administered premedication | degree of acceptance of the administered premedication | 30 minutes before induction of general anesthesia |
| evaluation of OZALIN® / OZASED® anxiolytic efficacy | OZALIN® / OZASED® anxiolytic efficacy was evaluated 30 minutes after premedication administration with the Ramsay sedation scale | 30 minutes after premedication administration |
| child's behavior on separation from the parent | Child's behavior at the moment of separation from the parent just before induction of anesthesia was evaluated with a four-point Parental Separation Anxiety scale (PSAS) | baseline (before induction of general anesthesia) |
| occurrence of delirium at the emergence from anesthesia | The occurrence of emergence delirium at the end of the procedure was measured using the five items of the Pediatric Anesthesia Emergence Delirium scale (PAED) | at emergence of anesthesia procedure |
| evaluation of behavioural changes seven days after the procedure, between the two groups. | Maladaptive behavioural responses and developmental regression seven days after the procedure were evaluated by parents of children with the Post Hospitalization Behaviour Questionnaire for Ambulatory Surgery (PHBS-AS). | 7 days after the magnetic resonance Imaging |
| ID | Term |
|---|---|
| D000067877 | Autism Spectrum Disorder |
| D001932 | Brain Neoplasms |
| ID | Term |
|---|---|
| D002659 | Child Development Disorders, Pervasive |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
| D016543 | Central Nervous System Neoplasms |
| D009423 | Nervous System Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D001927 | Brain Diseases |
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
Not provided
Not provided